AP625A - Pyrrolidinyl hydroxamic acid compounds and their production process. - Google Patents

Pyrrolidinyl hydroxamic acid compounds and their production process. Download PDF

Info

Publication number
AP625A
AP625A APAP/P/1996/000791A AP9600791A AP625A AP 625 A AP625 A AP 625A AP 9600791 A AP9600791 A AP 9600791A AP 625 A AP625 A AP 625A
Authority
AP
ARIPO
Prior art keywords
hydroxy
phenyl
compound
acetamide
formula
Prior art date
Application number
APAP/P/1996/000791A
Other languages
English (en)
Other versions
AP9600791A0 (en
Inventor
Fumitaka Ito
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9600791A0 publication Critical patent/AP9600791A0/xx
Application granted granted Critical
Publication of AP625A publication Critical patent/AP625A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
APAP/P/1996/000791A 1995-03-31 1996-03-14 Pyrrolidinyl hydroxamic acid compounds and their production process. AP625A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9500631 1995-03-31

Publications (2)

Publication Number Publication Date
AP9600791A0 AP9600791A0 (en) 1996-04-30
AP625A true AP625A (en) 1997-12-24

Family

ID=14125824

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1996/000791A AP625A (en) 1995-03-31 1996-03-14 Pyrrolidinyl hydroxamic acid compounds and their production process.

Country Status (35)

Country Link
US (2) US5952369A (is)
EP (1) EP0817772B1 (is)
JP (1) JP3035356B2 (is)
KR (1) KR100258657B1 (is)
AP (1) AP625A (is)
AR (1) AR002729A1 (is)
AT (1) ATE231840T1 (is)
AU (1) AU693336B2 (is)
BG (1) BG62611B1 (is)
BR (1) BR9607750A (is)
CA (1) CA2213815C (is)
CZ (1) CZ306497A3 (is)
DE (1) DE69626009T2 (is)
DK (1) DK0817772T3 (is)
ES (1) ES2188743T3 (is)
HR (1) HRP960141A2 (is)
HU (1) HUP9900767A3 (is)
IL (2) IL117440A0 (is)
IS (1) IS4547A (is)
LV (1) LV11971B (is)
MA (1) MA23832A1 (is)
NO (1) NO974513D0 (is)
NZ (1) NZ304113A (is)
OA (1) OA10518A (is)
PE (1) PE43397A1 (is)
PL (1) PL322652A1 (is)
RU (1) RU2144917C1 (is)
SI (1) SI9620039A (is)
SK (1) SK129897A3 (is)
TN (1) TNSN96045A1 (is)
TR (1) TR199701082T1 (is)
TW (1) TW408111B (is)
WO (1) WO1996030339A1 (is)
YU (1) YU18696A (is)
ZA (1) ZA962476B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701042A (es) * 1996-02-07 1998-05-31 Pfizer Compuestos del acido hidroxamico.
TNSN97092A1 (ar) * 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
CN1104239C (zh) * 1996-12-02 2003-04-02 杏林制药株式会社 新颖的n-取代的吡咯烷衍生物及其制备方法
EP0973737A4 (en) * 1997-01-10 2000-04-26 Merck & Co Inc EFFICIENT SYNTHESIS OF A CHIRAL MEDIATOR
EP0982297A3 (en) * 1998-08-24 2001-08-01 Pfizer Products Inc. Process for the preparation of hydroxy-pyrrolidinyl hydroxamic acid derivatives being opioid kappa receptor agonists
KR100295740B1 (ko) * 1998-09-17 2001-11-05 박영구 N-치환된-하이드록시고리화알킬아민유도체의제조방법
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
JP2005508851A (ja) 2001-04-30 2005-04-07 ファイザー・プロダクツ・インク カッパーアゴニストとして有用なヒドロキシピロリジニルエチルアミン化合物の調製方法
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
WO2004039785A1 (en) * 2002-11-01 2004-05-13 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
JP2006523670A (ja) * 2003-04-14 2006-10-19 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 5−(4−フルオロフェニル)−1−[2−((2r,4r)−4−ヒドロキシ−6−オキソ−テトラヒドロ−ピラン−2−イル)エチル]−2−イソプロピル−4−フェニル−1h−ピロール−3−カルボン酸フェニルアミドの調製方法
UA89035C2 (ru) * 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
GB0821010D0 (en) * 2008-11-17 2008-12-24 Univ Warwick Plant development control composition
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
KR101773331B1 (ko) * 2012-03-05 2017-08-31 닥터 레디스 레보러터리즈 리미티드 카파 오피오이드 수용체(κor) 작용제인 치환된 헤테로시클릭 아세트아미드
GB201210395D0 (en) * 2012-06-11 2012-07-25 Syngenta Participations Ag Crop enhancement compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268539A (en) * 1963-05-20 1966-08-23 Universal Oil Prod Co Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268539A (en) * 1963-05-20 1966-08-23 Universal Oil Prod Co Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters

Also Published As

Publication number Publication date
MA23832A1 (fr) 1996-10-01
CA2213815A1 (en) 1996-10-03
BG101896A (en) 1999-01-29
RU2144917C1 (ru) 2000-01-27
CA2213815C (en) 2001-12-18
HUP9900767A3 (en) 2001-01-29
IL129479A0 (en) 2000-02-29
KR100258657B1 (ko) 2000-07-01
IS4547A (is) 1997-08-19
EP0817772B1 (en) 2003-01-29
DE69626009T2 (de) 2003-08-14
DK0817772T3 (da) 2003-05-19
IL117440A0 (en) 1996-07-23
SK129897A3 (en) 1998-11-04
AP9600791A0 (en) 1996-04-30
AR002729A1 (es) 1998-04-29
ES2188743T3 (es) 2003-07-01
US6110947A (en) 2000-08-29
SI9620039A (sl) 1998-08-31
NO974513L (no) 1997-09-29
HUP9900767A2 (hu) 1999-07-28
KR19980703476A (ko) 1998-11-05
NZ304113A (en) 1999-01-28
JP3035356B2 (ja) 2000-04-24
HRP960141A2 (en) 1997-10-31
TNSN96045A1 (fr) 2005-03-15
NO974513D0 (no) 1997-09-29
PE43397A1 (es) 1997-10-13
TW408111B (en) 2000-10-11
BG62611B1 (bg) 2000-03-31
TR199701082T1 (xx) 1998-02-21
EP0817772A1 (en) 1998-01-14
LV11971A (lv) 1998-02-20
US5952369A (en) 1999-09-14
BR9607750A (pt) 1998-06-30
YU18696A (sh) 1999-06-15
LV11971B (en) 1998-06-20
AU5121196A (en) 1996-10-16
AU693336B2 (en) 1998-06-25
JPH11501048A (ja) 1999-01-26
WO1996030339A1 (en) 1996-10-03
OA10518A (en) 2002-04-22
PL322652A1 (en) 1998-02-16
CZ306497A3 (cs) 1998-07-15
ZA962476B (en) 1997-09-29
ATE231840T1 (de) 2003-02-15
DE69626009D1 (de) 2003-03-06
MX9707454A (es) 1998-07-31

Similar Documents

Publication Publication Date Title
EP0817772B1 (en) Pyrrolidinyl hydroxamic acid compounds and their production process
RU2125041C1 (ru) Арилацетамиды, способ их получения, фармацевтическая композиция и способ ее получения
DE69417427T2 (de) Indol- und indolin-derivate als 5ht1d rezeptor antagonisten
JP2935899B2 (ja) ▲下k▼レセプターアゴニストとしてのn−(2−(ピロリジニル−1)−1−フェニルエチル)アセトアミド
US6294557B1 (en) Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists
CA2069423A1 (en) Azacyclic derivatives
EP0789021B1 (en) Hydroxamic acid compounds as opioid kappa receptor agonists
JPH08502738A (ja) アミド誘導体
US5322852A (en) Aminooxy piperidines as ornithine decarboxylase inhibitors
JP3245578B2 (ja) ピロリジニルヒドロキサム酸化合物の製造方法
NZ233002A (en) 3-(aminoalkyl)benzothiopyran derivatives and pharmaceutical compositions
JP3233276B2 (ja) カッパアゴニストとしてのヒドラジド化合物
EP1870396B1 (en) Benzyloxypropylamine derivative
MXPA97007454A (en) Hydroxamic pirrolidinil acid compounds and their product procedure
JP2012107006A (ja) N−置換−環状アミノ誘導体の製造方法
PT789021E (pt) Compostos de acido pirrolidinil hidroxamico e o processo para a sua producao
KR19990028550A (ko) 편두통 치료용의 1,6-이치환된 이소크로만